The Genetics Company, Discovery Partners to Screen Drug Candidates for Colon Cancer | GenomeWeb

NEW YORK, Sept. 24 – The Genetics Company and Discovery Partners have partnered to identify potential drug targets for colon cancer, the companies said on Monday.

Discovery Partners, of San Diego, will screen thousands of chemical compounds for their ability to inhibit a protein that The Genetics Company has in previous studies linked to colon cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.